Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[finesand]

Little Update (Crossing TASE)

In regards to any pharma copying this combo indication, notice the Patent protection & FDA approval/exclusivity, you don't get it for nonsense.
Changshan also doesn't pay for nonsense, Chinese business man are the most cheap and watching their pennies :)

(SeaOfSand and I keep tracking, and it is reversing, 3rd reversal candle today)

- Priced below Consensi Approval & NT219 Ownership
- Priced at FDA refuted Consensi data falsification allegations on July'17
- Consensi: $2.40/sh for China + Korea
- Consensi: $3.94/sh for US + CA -> $6.79/sh Total
- Changshan paid $1M (May'18) and will pay additional $2.5M for regulatory and up to $6M for commercial milestones
- Changshan in CFDA process, which is a formality having FDA approval lately
- Changshan & Korea 12% Net Royalties, same expected for US
- Awaiting deal with US pharma
- 2018-06-01 Annual offering 3.26M @ $2.50/ads (still)
- 2018-06-19 HC Wainwright last Buy PT $12.50/sh
- FDA Exclusivity until 2021-05-31
- U.S. Patent 9,408,837: Filed 2011-02-14; Granted 2016-08-09; Term until 2031-02-14
- U.S. Patent 9,662,315: Filed 2015-11-10; Granted 2017-05-30; Term until 2035-11-10


Daily TASE/NSDQ


Evaluation